The antimicrobial armamentarium

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The treatment of infectious complications in the cancer patient has evolved as a consequence of the developments in cancer chemotherapy, which significantly impair immune function. Broad-spectrum, single-agent antibiotics have replaced more cumbersome multidrug regimens for empiric coverage of fever and neutropenia in many institutions. The use of new, potent oral antibiotics may be a next step toward further simplifications. Several new antivirals have come into clinical use in the past decade, and reports of viral resistance to the standard agent, acyclovir, have come forth. Increasing experience with new (and older) antifungal and antiparasitic agents has given a better understanding of the use of these drugs for both prophylaxis and treatment. This overview includes a critical appraisal of the attributes and limitations of current antibiotics, antivirals, antifungals, and antiparasitic agents for the immunocompromised host.

Original languageEnglish (US)
Pages (from-to)813-839
Number of pages27
JournalHematology/Oncology Clinics of North America
Volume7
Issue number4
StatePublished - Aug 13 1993
Externally publishedYes

Fingerprint

Antiparasitic Agents
Antifungal Agents
Anti-Bacterial Agents
Antiviral Agents
Acyclovir
Immunocompromised Host
Neutropenia
Neoplasms
Fever
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The antimicrobial armamentarium. / Freifeld, Alison Gail.

In: Hematology/Oncology Clinics of North America, Vol. 7, No. 4, 13.08.1993, p. 813-839.

Research output: Contribution to journalReview article

@article{e21f8f69f4844dae960617a5a41f9b4c,
title = "The antimicrobial armamentarium",
abstract = "The treatment of infectious complications in the cancer patient has evolved as a consequence of the developments in cancer chemotherapy, which significantly impair immune function. Broad-spectrum, single-agent antibiotics have replaced more cumbersome multidrug regimens for empiric coverage of fever and neutropenia in many institutions. The use of new, potent oral antibiotics may be a next step toward further simplifications. Several new antivirals have come into clinical use in the past decade, and reports of viral resistance to the standard agent, acyclovir, have come forth. Increasing experience with new (and older) antifungal and antiparasitic agents has given a better understanding of the use of these drugs for both prophylaxis and treatment. This overview includes a critical appraisal of the attributes and limitations of current antibiotics, antivirals, antifungals, and antiparasitic agents for the immunocompromised host.",
author = "Freifeld, {Alison Gail}",
year = "1993",
month = "8",
day = "13",
language = "English (US)",
volume = "7",
pages = "813--839",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The antimicrobial armamentarium

AU - Freifeld, Alison Gail

PY - 1993/8/13

Y1 - 1993/8/13

N2 - The treatment of infectious complications in the cancer patient has evolved as a consequence of the developments in cancer chemotherapy, which significantly impair immune function. Broad-spectrum, single-agent antibiotics have replaced more cumbersome multidrug regimens for empiric coverage of fever and neutropenia in many institutions. The use of new, potent oral antibiotics may be a next step toward further simplifications. Several new antivirals have come into clinical use in the past decade, and reports of viral resistance to the standard agent, acyclovir, have come forth. Increasing experience with new (and older) antifungal and antiparasitic agents has given a better understanding of the use of these drugs for both prophylaxis and treatment. This overview includes a critical appraisal of the attributes and limitations of current antibiotics, antivirals, antifungals, and antiparasitic agents for the immunocompromised host.

AB - The treatment of infectious complications in the cancer patient has evolved as a consequence of the developments in cancer chemotherapy, which significantly impair immune function. Broad-spectrum, single-agent antibiotics have replaced more cumbersome multidrug regimens for empiric coverage of fever and neutropenia in many institutions. The use of new, potent oral antibiotics may be a next step toward further simplifications. Several new antivirals have come into clinical use in the past decade, and reports of viral resistance to the standard agent, acyclovir, have come forth. Increasing experience with new (and older) antifungal and antiparasitic agents has given a better understanding of the use of these drugs for both prophylaxis and treatment. This overview includes a critical appraisal of the attributes and limitations of current antibiotics, antivirals, antifungals, and antiparasitic agents for the immunocompromised host.

UR - http://www.scopus.com/inward/record.url?scp=0027248584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027248584&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 813

EP - 839

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -